Clinical evaluation of CS-600 (Loxoprofen sodium) on postexodontic pain

—A multi-clinic double-blind study—

Abstract

Clinical usefulness of CS-600 (Loxoprofen sodium) for postexodontic pain was investigated by a double-blind study.
To estimate the optimal dose of the drug, a preliminary study was made using CS-600 at dosages of 20 and 40 mg. Then, a comparative study was made using CS-600 at 60 and 120 mg and mephenamic acid at 500 mg.
1) Based on the preliminary test results, the optimal dose of the drug was estimated as more than 40 mg.
2) In the total of 275 subjects, a comparative study was conducted, 85 subjects received CS-600 at 60 mg, 93 received CS-600 at 120 mg and 97 received mephenamic acid at 500 mg.
3) Analgesic effects were obtained in 88.2 % of the subjects treated with CS-600 at 60 mg, 91.4 % of those treated with CS-600 at 120 mg and 79.4 % of those with mephena-mic acid at 500 mg. Thus, CS-600 at 120 mg was demonstrated to be significantly superior to mephenamic acid at 500 mg.
4) The onset of the action was significantly more rapid in the subjects treated with CS-600 at 60 mg and 120 mg than in those treated with mephenamic acid at 500 mg.
5) Side effects were noticed in 2.4 % of the subjects treated with CS-600 at 60 mg, 5.3 of those with CS-600 at 120 mg and 3.1 % of those with mephenamic acid at 500 mg. Clinically severe side effects were not observed.
Our present study indicates that CS-600 at 60 mg or higher is equally effective or superior to mephenamic acid at 500 mg in relief of postexodontic pain and the onset of its action is very rapid. Thus, CS-600 was proven to be a clinically useful analgesic.